文献速递妇科

奥拉帕利维持治疗前对铂敏感复发性卵巢癌行二次肿瘤细胞减灭术是否仍有获益:病例对照研究

Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance: Still getting any benefit? A case-control study.
PubMed 文献 · Gynecol Oncol · 2019-10-09

病例对照研究纳入46例BRCA1/2突变铂敏感复发性卵巢癌患者,23例接受二次肿瘤细胞减灭术后化疗及奥拉帕利维持(SCS-CT-OLA组),23例仅接受化疗及奥拉帕利维持(CT-OLA组)。SCS-CT-OLA组中位至首次后续治疗时间显著更长(42个月 vs 16个月,p=0.05),3年复发后生存率更高(79% vs 42%,p=0.02)。作者认为二次肿瘤细胞减灭术可延长至首次后续治疗时间和复发后生存,需前瞻性研究验证,适应证应个体化。

要点

  • BRCA突变铂敏感复发性卵巢癌中,二次肿瘤细胞减灭术联合化疗及奥拉帕利维持较单纯化疗及奥拉帕利维持延长至首次后续治疗时间(42个月 vs 16个月,p=0.05)。
  • 二次肿瘤细胞减灭术组3年复发后生存率为79%,单纯化疗组为42%(p=0.02)。
  • 作者认为二次肿瘤细胞减灭术可延长至首次后续治疗时间和复发后生存,需前瞻性研究验证,适应证应个体化。

核心结论

  • 在BRCA1/2突变、铂敏感首次复发且对铂类化疗有反应后接受奥拉帕利维持的卵巢癌患者中,二次肿瘤细胞减灭术可延长至首次后续治疗时间和复发后生存。
  • 作者认为需前瞻性研究验证,在个体化医学时代二次肿瘤细胞减灭术的适应证应个体化。

研究设计与样本

  • 病例对照研究,2014年至2018年在本妇科肿瘤单位纳入46例BRCA1/2胚系或体细胞突变阳性的首次铂敏感复发性卵巢癌患者。
  • 病例组23例(50%)接受二次肿瘤细胞减灭术后铂类化疗及奥拉帕利维持(SCS-CT-OLA组),对照组23例(50%)仅接受化疗及奥拉帕利维持(CT-OLA组)。
  • 主要入组标准为BRCA1/2胚系或体细胞突变阳性,且在首次复发对铂类化疗有反应后接受奥拉帕利维持。

主要发现

  • 两组在年龄、突变状态、初诊治疗方式、复发时间及复发时疾病表现模式方面均衡,无统计学差异。
  • SCS-CT-OLA组中位至首次后续治疗时间为42个月,CT-OLA组为16个月(p=0.05)。
  • SCS-CT-OLA组3年复发后生存率为79%,CT-OLA组为42%(p=0.02)。

临床怎么用

  • 作者认为二次肿瘤细胞减灭术可延长BRCA突变铂敏感复发性卵巢癌患者的至首次后续治疗时间和复发后生存。
  • 作者认为需前瞻性研究验证,二次肿瘤细胞减灭术的适应证应个体化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The role of secondary cytoreductive surgery (SCS) in platinum-sensitive recurrent ovarian cancer (PSROC) is still controversial. We investigated the role of SCS in PSROC patients with BRCA1/2 mutation (BRCAmut) who received platinum-based chemotherapy followed by olaparib maintenance. METHODS: This is a case-control study. Patients with first PSROC admitted to our Gynecologic Oncology Unit between 2014 and 2018 were identified. Main eligibility criteria: positive BRCA1/2 germline or somatic mutation status and olaparib maintenance at primary recurrence after response to platinum-based chemotherapy. Cases were those who received SCS followed by medical treatment (SCS-CT-OLA, group 1), controls were those who received medical treatment alone (CT-OLA, group 2). RESULTS: Overall, 46 patients were identified; 23 (50%) BRCAmut women undergoing SCS followed by platinum-based chemotherapy and olaparib maintenance were matched with 23 (50%) BRCAmut women who only received medical treatment. Groups were well balanced: no statistical differences were found with regard of age, mutational status, treatment's approach at diagnosis, timing and patterns of disease presentation at recurrence. Median time to first subsequent therapy (TFST) was significantly longer in the SCS-CT-OLA than in the CT-OLA group (42 months vs 16 months; p = 0.05). Also, SCS-CT-OLA patients had the best post-recurrence survival (PRS), with a 3-year PRS of 79% in SCS-CT-OLA group versus 42% in CT-OLA group (p = 0.02). CONCLUSIONS: SCS increases TFST and PRS in PSROC patients with BRCAmut candidate for olaparib maintenance after platinum-based chemotherapy. Prospective studies are needed. In the era of personalized medicine, indication to SCS should be individualized.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Marchetti C, Rosati A, Scaletta G, et al. Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance: Still getting any benefit? A case-control study. Gynecol Oncol. 2019. PMID: 31606285. doi:10.1016/j.ygyno.2019.09.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。